drugset / Trial / NCT00328367

Aripiprazole Augmentation for Clozapine-Treated Patients With Refractory Schizophrenia

NCT00328367

RandomizedSingle-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether aripiprazole augmentation is safe and effective in the treatment of clozapine-treated patients with refractory schizophrenia.

Timeline

Start
2005-12
Primary completion
2006-12
Completion
2008-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Aripiprazole Other / unclassified

Indications